^
Association details:
| Biomarker: | FBXW7 mutation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Jingzhuda (entinostat) (HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma
Excerpt:
This analysis confirmed the specific sensitivity of FBW7-mutant cancer cells to three distinct HDAC inhibitors, including the class I-specific inhibitor MS-275 (Entinostat) (Fig. 3F and Supplementary Fig. S3D).
DOI:
10.1158/2159-8290.CD-12-0417
